Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | APAF1 | O14727 | 1/20 | 0.53 |
| ▸ | GRK2 | P25098 | 1/20 | 0.53 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3990458 | 0.91 | POLB (0.46) | POLBAPAF1GRK2APOBEC3GMIF | |
| SCHEMBL3982892 | 0.85 | MIF (0.48) | MIFRAB9ANPC1 | |
| SCHEMBL3984065 | 0.83 | NPC1 (0.59) | MIFRAB9ANPC1SMN1; SMN2CYP1A2 | |
| SCHEMBL3983302 | 0.83 | MIF (0.47) | MIFRAB9ANPC1 | |
| SCHEMBL5994929 | 0.83 | POLB (0.56) | POLBAPAF1GRK2APOBEC3GMIF | |
| SCHEMBL14084024 | 0.83 | LMNA (0.50) | MIFSMN1; SMN2 | |
| SCHEMBL3983987 | 0.83 | LMNA (0.50) | MIFSMN1; SMN2 | |
| SCHEMBL6021765 | 0.83 | POLB (0.56) | POLBAPAF1GRK2APOBEC3GMIF | |
| SCHEMBL5997363 | 0.83 | APAF1 (0.53) | POLBAPAF1GRK2APOBEC3GMIF | |
| SCHEMBL5994924 | 0.83 | POLB (0.56) | POLBAPAF1GRK2APOBEC3GMIF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030004212-A1 | Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists | DEORAZIO RUSSELL JOSEPH (US) | 2003-01-02 | — | — | US | claimed |
| EP-1251128-A1 | Cyclohexylamine derivatives as subtype selective N-methyl-D-aspartate antagonists | WARNER-LAMBERT COMPANY (US) | 2002-10-23 | — | — | EP | claimed |
| US-6828341-B2 | Brain disorders; anticonvulsants; central nervous system disorders; psychological disorders | WARNER-LAMBERT COMPANY | 2004-12-07 | — | — | US | disclosed |
| US-20030004212-A1 | Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists | DEORAZIO RUSSELL JOSEPH (US) | 2003-01-02 | — | — | US | disclosed |
| EP-1251128-A1 | Cyclohexylamine derivatives as subtype selective N-methyl-D-aspartate antagonists | WARNER-LAMBERT COMPANY (US) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004212-A1 | Cyclohexylamine derivatives as subtype selective N-Methyl-D-Aspartate antagonists | GLRB, GRIN1, GRIN2B | POLB 429/4885APAF1 4855/4885GRK2 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.